This is a list of investigational aggression drugs, or drugs that are currently under development for clinical use in the treatment of aggression but are not yet approved. Drugs used to treat aggression may also be known as "serenics". Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in February 2025. It is likely to become outdated with time.
Under development
Phase 3 Molindone (AFX 2201; EN-1733A; -810; SPN-810M; Zalvari) – antipsychotic (dopamine D2 receptor antagonist, serotonin 5-HT2B receptor antagonist, and other actions) – specifically for aggression in children and adolescents with attention-deficit hyperactivity disorder (ADHD)
Phase 2 KNX-100 (SOC-1) – 15-lipoxygenase (15-LOX; ALOX15) inhibitor and oxytocin-like drug or indirect oxytocin receptor modulator [1] [2] Vafidemstat (ORY-2001) – lysine-specific demethylase 1 (LSD1; KDM1A) and monoamine oxidase B (MAO-B) inhibitor
Preclinical KNX-101 – 15-lipoxygenase (15-LOX; ALOX15) inhibitor SRX251 – vasopressin V1A receptor antagonist – no recent development since 2007
Not under development
No development reported Eltoprazine (DU-28853) – serotonin 5-HT1A and 5-HT1B receptor agonist and serotonin 5-HT2C receptor antagonist Zolmitriptan (ML-004) – serotonin 5-HT1B and 5-HT1D receptor agonist
Development discontinued Batoprazine – serotonin 5-HT1A and 5-HT1B receptor agonist Mibampator (LY-451395) – ionotropic glutamate AMPA receptor positive allosteric modulator Olanzapine intranasal (INP-105; POD olanzapine) – atypical antipsychotic (non-selective monoamine receptor modulator) Risperidone extended-release (Risperisphere) – atypical antipsychotic (non-selective monoamine receptor modulator)
Formal development never or not yet started Antiandrogens (e.g., cyproterone acetate, medroxyprogesterone acetate, GnRH modulators) Other serotonin 5-HT1A and 5-HT1B receptor agonists (e.g., fluprazine) Selective 5-HT1B receptor agonists (e.g., anpirtoline, CP-94253) Serotonin 5-HT1B and 5-HT1D receptor agonists (e.g., PGI-7043) Serotonin 5-HT2B receptor antagonists (e.g., MW073) Serotonin 5-HT2C receptor agonists (e.g., lorcaserin) Serotonin releasing agents (e.g., fenfluramine) Trace amine-associated receptor 1 (TAAR1) agonists (e.g., RO5263397)
Clinically used drugs
Approved drugs Olanzapine (Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) Paliperidone (Invega) – atypical antipsychotic (non-selective monoamine receptor modulator) Risperidone (Risperdal) – atypical antipsychotic (non-selective monoamine receptor modulator)
Off-label drugs α2-Adrenergic receptor agonists (e.g., clonidine, dexmedetomidine, guanfacine) Anticonvulsants (e.g., valproic acid, divalproex, carbamazepine, oxcarbazepine, phenytoin, lamotrigine, topiramate, gabapentin, tiagabine) Antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs) like sertraline) (but may exacerbate aggression) Benzodiazepines (e.g., diazepam, lorazepam, midazolam) (but may exacerbate aggression) Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, pindolol, nadolol) Cannabinoids (e.g., cannabis, dronabinol, nabilone) Lithium – mood stabilizer with unknown mechanism of action Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine) Other antipsychotics (e.g., aripiprazole, chlorpromazine, droperidol, haloperidol, quetiapine, thioridazine) Psychostimulants (e.g., amphetamine, methylphenidate) (but may exacerbate aggression)
See also List of investigational drugs List of investigational agitation drugs List of investigational antipsychotics List of investigational borderline personality disorder drugs List of investigational autism and pervasive developmental disorder drugs Serenic (antiaggressive drug) Anger § Medication therapy Entactogen
References
External links AdisInsight - Springer
